Status:

Red

Decision Date:

None

Comments

RED¹: NICE TA612 - for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab. (Decision date - December 2019)  

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again